LIGAND PHARMACEUTICALS INC (LGNDZ)
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Address
3911 SORRENTO VALLEY BLVD
SAN DIEGO, CA 92121
Founded
1987
Number of Employees
58
Website
http://www.ligand.com
Buyback
Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
$ Amount Purchased ($ in 000s ) |
$67,938 | $489 | $3,900 | $1,966 | $74,754 | $171,864 | $78,000 | - | - | - | - | $56,987 |
Average Price | $54.20 | $79.92 | $96.31 | $140.43 | $148.54 | $101.19 | $83.50 | - | - | - | - | $89.65 |
# Shares Purchased | 1,253,425 | 6,120 | 40,500 | 14,000 | 503,248 | 1,698,495 | 934,079 | - | - | - | - | 635,695 |
Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Return to Date | 91.9% | 30.1% | 8.0% | -25.9% | -30.0% | 2.8% | 24.5% | - | - | - | - | 16.0% |
S&P 500 Return to Date | 181.9% | 173.0% | 168.6% | 129.7% | 104.9% | 93.1% | 74.8% | - | - | - | - | 132.3% |
Excess Total Return | -90.0% | -142.8% | -160.6% | -155.7% | -134.9% | -90.3% | -50.3% | - | - | - | - | -116.3% |
Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
Percentile Rank | 56% | 42% | 34% | 25% | 21% | 36% | 43% | - | - | - | - | 53% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)